

Supplemental Table 1. Cohort and clinicopathological data for lung cores.

	Non-responders	Responders
Sex		
Female	3 (60.0%)	0 (0%)
Male	2 (40.0%)	6 (100.0%)
Age (\pm SD)	62.2 \pm 8.8	69.0 \pm 8.8
Smoking Status		
Smoker	5 (100.0%)	6 (100.0%)
Histology		
Adenocarcinoma	5 (100.0%)	4 (66.6%)
Squamous	0 (0%)	2 (33.3%)
Stage at diagnosis		
IA3	1 (20.0%)	0 (0%)
IIB	0 (0%)	2 (33.3%)
IIIA	3 (60.0%)	4 (66.6%)
IVA	1 (20.0%)	0 (0%)
Specimen		
Biopsy	1 (20.0%)	0 (0%)
Surgical resection	4 (80.0%)	6 (100.0%)
Radiation		
Yes	2 (40.0%)	4 (66.6%)
No	3 (60.0%)	2 (33.3%)
Chemotherapy		
Yes	5 (100.0%)	6 (100.0%)
No	0 (0%)	0 (0%)
Immunotherapy		
Atezolizumab	1 (20.0%)	1 (16.7%)
Nivolumab	4 (80.0%)	2 (33.3%)
Pembrolizumab	0 (0%)	3 (50.0%)
Progression-free survival (\pm SD)	3.0 months \pm 2.1 months	19.4 months \pm 12.3 months
Overall survival (\pm SD)	10.0 months \pm 7.0 months	32.3 months \pm 15.0 months